These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 7693562)
21. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Eberhard A; Kahlert S; Goede V; Hemmerlein B; Plate KH; Augustin HG Cancer Res; 2000 Mar; 60(5):1388-93. PubMed ID: 10728704 [TBL] [Abstract][Full Text] [Related]
22. Mechanisms and significance of bifunctional NK4 in cancer treatment. Matsumoto K; Nakamura T Biochem Biophys Res Commun; 2005 Jul; 333(2):316-27. PubMed ID: 15950947 [TBL] [Abstract][Full Text] [Related]
23. VEGF inhibition: insights from preclinical and clinical studies. Crawford Y; Ferrara N Cell Tissue Res; 2009 Jan; 335(1):261-9. PubMed ID: 18766380 [TBL] [Abstract][Full Text] [Related]
24. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Glade Bender J; Cooney EM; Kandel JJ; Yamashiro DJ Drug Resist Updat; 2004; 7(4-5):289-300. PubMed ID: 15533766 [TBL] [Abstract][Full Text] [Related]
25. Endothelial survival factors as targets for antineoplastic therapy. Reinmuth N; Stoeltzing O; Liu W; Ahmad SA; Jung YD; Fan F; Parikh A; Ellis LM Cancer J; 2001; 7 Suppl 3():S109-19. PubMed ID: 11779081 [TBL] [Abstract][Full Text] [Related]
26. Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed. ten Hagen TL; Seynhaeve AL; Eggermont AM Immunol Rev; 2008 Apr; 222():299-315. PubMed ID: 18364010 [TBL] [Abstract][Full Text] [Related]
28. [Angiogenesis and its inhibitors]. Ono M; Kuwano M Gan To Kagaku Ryoho; 1997 Sep; 24(11):1585-93. PubMed ID: 9309158 [TBL] [Abstract][Full Text] [Related]
29. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Horsman MR; Siemann DW Cancer Res; 2006 Dec; 66(24):11520-39. PubMed ID: 17178843 [TBL] [Abstract][Full Text] [Related]
30. [Vascularization and perfusion of tumors as target in cancer therapy]. Bernsen HJ; van der Kogel AJ; van Daal WA; Rijken PF Ned Tijdschr Geneeskd; 1997 Feb; 141(8):364-8. PubMed ID: 9157295 [TBL] [Abstract][Full Text] [Related]
34. [Angiogenesis and the regulation of antitumor defense]. Pappas NP; Hillen HF; Wagstaff J; Griffioen AW Ned Tijdschr Geneeskd; 1999 Jul; 143(30):1555-9. PubMed ID: 10443280 [TBL] [Abstract][Full Text] [Related]
35. Promoting angiogenesis to a fault. Hicklin DJ Nat Biotechnol; 2007 Mar; 25(3):300-2. PubMed ID: 17344881 [No Abstract] [Full Text] [Related]
36. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. O'Reilly MS EXS; 1997; 79():273-94. PubMed ID: 9002223 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of angiogenesis in cancer patients. Verheul HM; Pinedo HM Expert Opin Emerg Drugs; 2005 May; 10(2):403-12. PubMed ID: 15934875 [TBL] [Abstract][Full Text] [Related]